Plasma betatrophin levels in patients with liver cirrhosis : = Plasma betatrophin levels in patients with liver cirrhosis

AIM: To investigate the plasma levels of betatrophin in patients with cirrhosis.METHODS: Forty patients diagnosed at the clinic with liver cirrhosis according to biological, ultrasonographic,or histological criteria were included.The severity of cirrhosis was classified according to Pugh's modification of Child's classification and MELD score. Insulin resistance(IR) was assessed by the Homeostasis Model Assessment. A total of 20 patients showed a MELD score higher than 14. The control group consisted in 15 sex-and aged-matched subjects.Fasting blood samples were obtained for subsequent analysis. Serum insulin was determined by Liaison automated immune chemiluminiscence assay(DiaSorin S.p.A.) using a sandwich assay. The sensitivity of the assay was 0.2 μU/mL. The intra and interassay variation coefficients were < 4% and < 10%,respectively. The normal values were between 2 and17 μU/mL. Human active betatrophin was analyzed by specific quantitative sandwich ELISA(Aviscera Bioscience). The sensitivity of the assay was 0.4 ng/mL, and the intra and interassay reproducibility were< 6% and < 10%, respectively.RESULTS: Plasma betatrophin levels were significantly increased in patients with cirrhosis compared with those in healthy subjects(P = 0.0001). Betatrophin levels were also associated with disease severity, being higher in Child-Pugh C patients compared to Child-Pugh B(P< 0.0005) and in patients who displayed a MELD score higher than 14 points compared to patients with lower punctuation(P = 0.01). In addition, we found a positive correlation between plasma betatrophin levels and the severity of cirrhosis according to Child-Pugh classification(r = 0.53; P < 0.01) or MELD score(r = 0.45; P <0.01). In the overall cohort, a moderate correlation between serum betatrophin and plasmatic bilirrubin(r= 0.39; P < 0.01) has been observed, as well as an inverse correlation between betatrophin and albumin(r =-0.41; P < 0.01) or prothrombin time(r =-0.44;P <0.01). Moreover, insulin resistance was observed in82.5% of the cirrhotic patients. In this group of patients,betatrophin levels were significantly higher than those in the group of patients without IR(P < 0.05).CONCLUSION: Plasma betatrophin is increased in patients with cirrhosis. This increase is related to the severity of cirrhosis, as well as with the emergence of insulin resistance..

Medienart:

E-Artikel

Erscheinungsjahr:

2015-10-07

2015

Erschienen:

2015-10-07

Enthalten in:

Zur Gesamtaufnahme - year:2015

Enthalten in:

World journal of gastroenterology - (2015), 37 vom: 07. Okt., Seite 10662-10668

Original Letters: Enthalten in (DE-576)276271955 (DE-576)276271955

Reihe:

China Academic Journals (CAJ), E, 医药卫生科技 = Medicine & Public Health

Sprache:

Chinesisch

Weiterer Titel:

Plasma betatrophin levels in patients with liver cirrhosis

Beteiligte Personen:

Maria Teresa Arias-Loste [VerfasserIn]
Maria Teresa García-Unzueta [Sonstige Person]
Susana Llerena [Sonstige Person]
Paula Iruzubieta [Sonstige Person]
Angela Puente [Sonstige Person]
Joaquín Cabezas [Sonstige Person]
Carmen Alonso [Sonstige Person]
Antonio Cuadrado [Sonstige Person]
José Antonio Amado [Sonstige Person]
Javier Crespo [Sonstige Person]
Emilio Fábrega [Sonstige Person]

Links:

oversea.cnki.net [lizenzpflichtig]

Themen:

内科学
医药、卫生
医药卫生科技
消化系及腹部疾病
Digestive System Disease
Endocrinology Unit, Marqués de Valdecilla University Hospital,Instituto de Investigación Sanitaria Valdecilla, Avenida Valdecilla s/n, 39008 Santander, Cantabria, Spain
Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital,Instituto de Investigación Sanitaria Valdecilla,Avenida Valdecilla s/n, 39008 Santander, Cantabria, Spain
Medicine & Public Health

Anmerkungen:

Author info:Maria Teresa Arias-Loste;Maria Teresa García-Unzueta;Susana Llerena;Paula Iruzubieta;Angela Puente;Joaquín Cabezas;Carmen Alonso;Antonio Cuadrado;José Antonio Amado;Javier Crespo;Emilio Fábrega;Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital,Instituto de Investigación Sanitaria Valdecilla,Avenida Valdecilla s/n, 39008 Santander, Cantabria, Spain;Endocrinology Unit, Marqués de Valdecilla University Hospital,Instituto de Investigación Sanitaria Valdecilla, Avenida Valdecilla s/n, 39008 Santander, Cantabria, Spain

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CAJ489103596